The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit
This is Enzene Biosciences third biosimilar to be approved
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated
